Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 2
1998 1
1999 1
2010 1
2012 1
2013 1
2014 2
2015 1
2017 2
2018 1
2020 2
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

13 results
Results by year
Filters applied: . Clear all
Page 1
TriTACs, a Novel Class of T-Cell-Engaging Protein Constructs Designed for the Treatment of Solid Tumors.
Austin RJ, Lemon BD, Aaron WH, Barath M, Culp PA, DuBridge RB, Evnin LB, Jones A, Panchal A, Patnaik P, Ramakrishnan V, Rocha SS, Seto P, Sexton K, Strobel KL, Wall R, Yu S, Yu TZ, Law CL, Baeuerle PA, Wesche H. Austin RJ, et al. Among authors: culp pa. Mol Cancer Ther. 2021 Jan;20(1):109-120. doi: 10.1158/1535-7163.MCT-20-0061. Epub 2020 Nov 17. Mol Cancer Ther. 2021. PMID: 33203731 Free article.
Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors.
Lam ET, Eckhardt SG, Messersmith W, Jimeno A, O'Bryant CL, Ramanathan RK, Weiss GJ, Chadha M, Oey A, Ding HT, Culp PA, Keller SF, Zhao VY, Tsao LC, Singhal A, Holen KD, Von Hoff D. Lam ET, et al. Among authors: culp pa. Mol Cancer Ther. 2018 Jan;17(1):215-221. doi: 10.1158/1535-7163.MCT-17-0330. Epub 2017 Oct 20. Mol Cancer Ther. 2018. PMID: 29054986 Free PMC article. Clinical Trial.
Predictive gene signature of response to the anti-TweakR mAb PDL192 in patient-derived breast cancer xenografts.
de Plater L, Vincent-Salomon A, Berger F, Nicolas A, Vacher S, Gravier E, Thuleau A, Karboul N, Richardson M, Elbaz C, Marangoni E, Bièche I, Paoletti X, Roman-Roman S, Culp PA, Asselain B, Diéras V, Decaudin D. de Plater L, et al. Among authors: culp pa. PLoS One. 2014 Nov 6;9(11):e104227. doi: 10.1371/journal.pone.0104227. eCollection 2014. PLoS One. 2014. PMID: 25375638 Free PMC article.
Antibodies to TWEAK receptor inhibit human tumor growth through dual mechanisms.
Culp PA, Choi D, Zhang Y, Yin J, Seto P, Ybarra SE, Su M, Sho M, Steinle R, Wong MH, Evangelista F, Grove J, Cardenas M, James M, Hsi ED, Chao DT, Powers DB, Ramakrishnan V, Dubridge R. Culp PA, et al. Clin Cancer Res. 2010 Jan 15;16(2):497-508. doi: 10.1158/1078-0432.CCR-09-1929. Epub 2010 Jan 12. Clin Cancer Res. 2010. PMID: 20068083 Free article.
13 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page